Background/Aims: The adenosine A1 receptor (A1R) has been reported to be involved in the pathogenesis of various cancers, and the effects of A1R on different cancers are pleiotropic. However, the role of A1R in renal cell carcinoma (RCC) remains not well-known. Methods: The expression of A1R in RCC cells was detected by quantitative real-time PCR and Western blotting analysis. Cell proliferation was detected using an MTT assay and a colony formation assay. Tumor growth was also evaluated in nude mice. Cell invasion and migration were evaluated using a wound healing assay and a transwell assay. Cell cycle distribution and apoptosis rates were analyzed by flow cytometry. Results: A1R was the main subtype of ARs and was up-regulated in 786-O and ACHN cells. Functionally, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), an A1R antagonist, inhibited RCC cell proliferation in vitro and tumor growth in vivo. Furthermore, DPCPX inhibited RCC cell migration, while N 6 -Cyclopentyladenosine (CPA), a selective A1 agonist, was able to rescue RCC cell migration. In addition, DPCPX promoted 786-O and ACHN cell apoptosis and induced an S phase cell cycle arrest. Finally, we demonstrated that DPCPX inhibited tumor progression in part via the ERK/JNK pathway. Conclusion: These findings suggest the potentially important role of DPCPX in the control of RCC cell proliferation and migration by regulating the ERK/JNK signaling pathway.
Introduction
Renal cell carcinoma (RCC) is the third most common urologic tumor, accounting for approximately 3% to 4% of all human malignancies [1] . To date, surgical therapy is the main treatment for localized RCC. Although remarkable progress has been made in the diagnosis of RCC, approximately 30% of patients experience locally advanced or metastasis at initial diagnosis [2] . Due to its poor response to radiotherapy and chemotherapy, the 5-year survival rate of metastatic RCC is only 10% [3] . Recently, molecular targeted therapy has significantly improved the prognosis for patients with metastatic RCC. However, it also has several limitations, such as severe side effects and drug tolerance [4, 5] . Therefore, it is of great urgency to seek the underlying molecular mechanisms of tumor progression in RCC.
Adenosine is a nucleoside that plays an important role in the carcinogenesis and progression of diverse cancers, and is broken down into inosine by adenosine deaminase [6] . The biological functions of adenosine are mediated via four G protein-coupled adenosine receptors (ARs): A1, A2a, A2b, and A3 [7] . The adenosine A1 receptor (A1R) has been reported to be involved in the pathogenesis of various cancers, including breast, colon, astrocytoma, and gastric cancers [8] [9] [10] [11] . Hosseinzadeh et al. [12] found that A1R agonists, such as CHA or R-PIA, inhibited cell proliferation in HepG2 and CACO2 cell lines. These effects could be partially inhibited by using A1R antagonist. In contrast, a study by Lin et al. [13] showed that A1R antagonist reduced proliferation in MCF-7 cells. Furthermore, knockdown of A1R by siRNA decreased cell proliferation, but over-expression of A1R could increase cell proliferation. Thus, the effects of A1R on different cancers are pleiotropic. To our knowledge, information on the expression of A1R and its biological functions in RCC is limited.
In this study, we first revealed that expression of A1R was up-regulated in RCC cells compared to the human renal tubular epithelial cell line HK-2. Then, we investigated the effects of A1R antagonist on cell proliferation, tumor growth and migration. The underlying molecular mechanisms were also explored. This study provides new understanding of the role of A1R in tumor progression in RCC.
Materials and Methods

Cell culture and reagents
The human kidney cancer cell line 786-O (primary renal carcinoma cell), ACHN (metastatic renal carcinoma cell) cells, and the renal tubular epithelial cell line HK-2 were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Science (Shanghai, China). The cells were cultured in RMPI 1640 medium (HyClone, USA) supplemented with 10% fetal bovine serum (HyClone, USA) at 37°C under 5% CO2. 1, 3-dipropyl-8-cyclopentylxanthine (DPCPX), an A1R antagonist, and N 6 -Cyclopentyladenosine (CPA), a selective A1R agonist, were purchased from Abcam (ab120396 and ab120398, USA). DPCPX and CPA were dissolved in dimethyl sulfoxide (DMSO).
Quantitative real-time PCR
Total RNA was extracted from 786-O, ACHN and HK-2 cells using Trizol Reagent (Invitrogen, USA) according to the manufacturer's instructions. Quantitative real-time PCR was performed by using the SYBR Green PCR kit (Toyobo, Japan). β-actin was used as the internal control. The primer sequences are shown in Table 1 .
Western blot 786-O and ACHN cells were treated with DPCPX (10μM and 25μM) for 48 h. Samples were detected according to procedures previously described [14] . β-actin was used as the loading control. The following antibodies against ERK (#4695), p-ERK (#4370), JNK (9252), p-JNK (#4668), MMP-2 (#13132), MMP-9 (#13667) and β-actin (#12620) were purchased from Cell Signaling Technology. Antibodies against cyclin B1 (55004-1-AP), cyclin D (60186-1-Ig), Bcl-2 (60178-1-Ig) and Bax (60267-1-Ig) were obtained from Proteinch. The antibody against A1R (ab124780) was obtained from Abcam.
MTT assay 786-O and ACHN cells were seeded into 96-well plates at 2000 cells/well. The cells were treated with DPCPX (from 0.01μM to 40μM) for 48 h. 20μl of MTT-medium mixed solution (0.5 mg/ml) were added to each well for 4 h of incubation. After the formazan sediment was dissolved using 150μl DMSO, the absorbance at 490nm was measured on a microplate reader. All experiments were performed in triplicate. 
Colony formation assay 786-O and ACHN cells were seeded into 6-well plates (800 cells per well). DPCPX (10μM and 25μM) was added to the well. After culturing for 12-14 days, proliferating colonies were stained with crystal violet, and colonies containing more than 50 cells were counted. All experiments were performed in triplicate.
Wound healing assay 786-O and ACHN cells were plated into 6-well plates and maintained to 100% confluence. The wounds were scratched using pipette tips and washed with PBS to remove cellular debris. After that, DPCPX (10μM and 25μM) was added to the well with/without the pretreatment of CPA (1μM) for 2 h. Images were taken immediately and at 36/48 h after wounding. The width of the cell-free area was measured, and the percentage of migration was considered to be the ratio of the reduction of width to the initial width of the scraped area (0 h).
Transwell assay 786-O and ACHN cells were cultivated with serum-free culture medium for 24 hours. Transwell chambers (Corning, USA) were placed into the 24-well plates. The lower chambers contained medium with 10% FBS, while the cells were added into the upper chambers with serum-free medium. Then DPCPX (10μM and 25μM) was added to the upper chambers with/without the pretreatment of CPA (1μM) for 2 h, and the cells that migrated through the membrane were stained and counted.
Flow cytometry 786-O and ACHN cells were treated with DPCPX (10μM and 25μM) for 48 h. For an apoptosis analysis, cells were harvested and stained with Annexin V and propidium iodide (BD, USA). For a cell cycle analysis, cells were harvested and fixed overnight with ice-cold 70% ethanol. The cells were then stained with 0.5 ml of propidium iodide and RNase (BD, USA). Both the apoptosis and cell cycle analyses were evaluated using a flow cytometer (FACSCalibur, BD).
Xenograft assays in nude mice
786-O and ACHN cells (5×10
6
) were injected subcutaneously into the right flank of 6-week-old BABL/c nude mice (n=5 for each group). For the DPCPX treatment group, DPCPX (1 mg/kg) was injected every two days until the mice were sacrificed. Starting five days after implantation, tumor volume was measured twice a week and calculated according to the formula: tumor volume (mm Statistical analysis SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. All experiments were performed in triplicate and the results were presented as the mean ± SD. A two-tailed unpaired Student's t-test and one-way ANOVA were performed. P value < 0.05 was considered to be statistically significant.
Results
A1R expression is the highest in all four subtypes of ARs and up-regulated in RCC cells
To explore the expression of A1R in RCC cells, the mRNA and protein levels of A1R were evaluated. It was shown that the expression of A1R was higher than the other three ARs in 786-O and ACHN cells (Fig. 1A) . To verify the mRNA expression findings of A1R, a 
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investigate the effect of DPCPX on the expression of A1R, 786-O and ACHN cells were treated with DPCPX (10μM and 25μM) for 48 h. Then, the mRNA level of A1R was evaluated, and the results showed that the mRNA expression of A1R was not affected by DPCPX (Fig. 1C) . These findings showed that A1R was the main subtype of ARs and was up-regulated in RCC cells.
DPCPX inhibits cell proliferation in vitro and tumor growth in vivo in RCC cells
To investigate the effect of A1R in RCC cells, we first determined whether DPCPX affected 786-O and ACHN cell proliferation. An MTT assay indicated that DPCPX suppressed the cellular growth in a dose-depended manner ( Fig. 2A) . Lower concentrations of DPCPX (1μM and 5μM) had no significant effect on cell viability, but a significant inhibitory effect started at 10μM. The IC50 values of DPCPX in 786-O and ACHN cells were 43.0±4.1μM and 51.8±4.7μM respectively. Similar results were shown in the colony formation assay (Fig. 2B) . DPCPX (10μM and 25μM) significantly reduced the number of colonies when compared to the DMSO group. These findings suggested that DPCPX could regulate the proliferation of RCC cells in vitro. To further explore the inhibitory capacity on proliferation, we assessed the potential role of DPCPX on tumor growth in vivo. After 786-O and ACHN cells were inoculated subcutaneously into the nude mice, DPCPX was injected every two days until the mice were sacrificed. We found that the average tumor volume decreased in the DPCPX group, compared to the DMSO group (Fig. 2C and D) . These data indicated that DPCPX could inhibit RCC cell proliferation and tumor growth.
DPCPX inhibits cell migration in RCC cells
Next, we investigated the role of DPCPX in regulating RCC cell migration. As shown in cells than the control group in wound healing assay (P<0.001). Additionally, the results of the transwell assay showed an obvious decrease in the number of migrated cells in the DPCPX group relative to the control group (Fig. 3B ). To further explore the effect of A1R on cell migration in RCC cells, 1μM N 6 -Cyclopentyladenosine (CPA), a selective A1 agonist, was used in both the wound healing assay and the transwell assay. Our results showed that there was no difference between the CPA group and the control group (Fig. 4A) . However, CPA could rescue RCC cell migration (Fig. 4B and C) . MMP-2 and MMP-9 have been considered important regulators in tumor migration and invasion. Notably, the protein level of MMP-2 and MMP-9 were down-regulated by treatment with DPCPX in our study (Fig. 3C) . These findings indicated that DPCPX could inhibit the capacity of RCC cell migration.
DPCPX promotes RCC cell apoptosis and induces an S phase cell cycle arrest
As described above, DPCPX could inhibit RCC cell proliferation. Further experiments were performed to detect the effect of DPCPX on cell apoptosis and cell cycle. After treatment with DPCPX at concentrations of 10μM and 25μM, 786-O and ACHN cells exhibited markedly increased apoptotic rates of 29.61 ± 1.43%, 45.11 ± 2.34% and 30.87 ± 1.65%, 38.77 ± 1.36%, respectively, compared to the control group (3.07 ± 0.65%, 2.90 ± 0.82%) (Fig. 5A) . We then examined the protein level of Bcl-2 and Bax, which play a key role in mitochondrialmediated apoptosis. Our results showed that DPCPX down-regulated the Bcl-2 expression but up-regulated the level of Bax (Fig. 5C) . Together, these data showed that DPCPX induced mitochondrial-dependent apoptosis in RCC cells. 
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Next, cell cycle distribution analyses were performed. The population of the control group in phase S was 32.43 ± 1.44% and 37.43 ± 1.68%, whereas the percent distribution of cells in phase S treated with DPCPX at 10μM and 25μM were 36.46 ± 1.32%, 46.98 ± 0.90% and 43.90 ± 2.04%, 51.56 ± 0.71% in 786-O and ACHN cells, respectively, showing a dosedependent increase (Fig. 5B) . A decrease in the population of cells in the G0/G1 phase was 
DPCPX inhibits the phosphorylation of the ERK/JNK pathway
To explore the mechanism underlying the inhibitory effect of DPCPX on cell proliferation, tumor growth, and migration, the protein levels of relevant proteins in the ERK and JNK pathways were determined. Our results showed that treatment with DPCPX significantly decreased the phosphorylation of ERK and JNK (Fig. 6 ), indicating that DPCPX might inhibit tumor progression in part via the ERK/JNK pathway in RCC.
Discussion
A1R activation has been reported in various cancers. It was greatly up-regulated in the colon cancer cell line CW-2 and the breast cancer cell line MDA-MB-468, compared to their matched normal cells [15] . Similarly, Khoo et al. [16] found that the mRNA level of A1R was higher in human colorectal adenocarninoma tissue than in peritumoral normal tissues. In the present study, we selected two widely researched kidney cancer cell lines 786-O and ACHN, and analyzed the expression of ARs. Our results showed that the level of A1R was the highest of all four subtypes of ARs and was up-regulated compared to the normal renal tubular epithelial cells. These data suggest that A1R may play a role in RCC cells.
A1R agonists and antagonists have been used to explore the effects of A1R on various cancers. However, the results are controversial. It has been documented that the A1R agonist could inhibit cell proliferation in colonic cancer, astrocytoma and melanoma cells [9, 10, 17] . In contrast, several studies also showed that the A1R antagonists could reduce cell proliferation [13, 18] . Notably, a combined treatment with A1R agonist and temozolomide significantly inhibited cell proliferation and promoted apoptosis compared to temozolomide alone in cancer stem cells [19] , whereas A1R antagonist DPCPX was found to significantly induce apoptosis in MCF-7 cells [18] . In this study, the expression of A1R was up-regulated; thus, the A1R antagonist DPCPX was used. Our results revealed that DPCPX reduced cell proliferation in vitro and inhibited tumor growth in vivo. We also found that DPCPX increased apoptosis and modulated the expression of Bcl-2 and Bax, which are mitochondrialmediated apoptosis relevant proteins [20] [21] [22] . Additionally, Mirza et al. [8] demonstrated that knocking down the expression of A1R by siRNA led to an S/G2 cell arrest in breast cancer cells. Concurrently, in the present study, blockade of A1R by DPCPX treatment also accumulated RCC cells in the S phase. Furthermore, two cell cycle regulatory proteins linked 
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Cellular Physiology and Biochemistry to the S phase transition, cyclin B1 and cyclin D, were found to be modulated by DPCPX. In light of these findings, we believe that DPCPX inhibits RCC cell proliferation by promoting apoptosis and regulating the cell cycle. Interestingly, our results also revealed that DPCPX reduced the migratory capacity of RCC cells in a dose-dependent manner. Moreover, CPA could rescue RCC cell migration. MMP-2 and MMP-9 have been considered important regulators in tumor migration and invasion [23] [24] [25] . Li et al. [26] found that stimulating A1R with an A1R agonist increased MMP-2 and MMP-9 release, and this release could be blocked by the A1R antagonist DPCPX in human trabecular meshwork cells. In an in-vivo study by Puhl et al. [27] , an A1R agonist inhibited the expression of cleaved MMP-2. These studies indicated A1R might be linked to MMP-2 and MMP-9. In the present study, the protein levels of MMP-2 and MMP-9 were determined and revealed that treatment with DPCPX could reduce the expression of MMP-2 and MMP-9. In this regard, we consider DPCPX to inhibit the migratory capacity by regulating the expression of MMPs in RCC cells.
The ERK/JNK pathway is an important cell signaling mechanism involved in multiple cell functions. Previous studies have indicated that the activation of A1R may be associated with the ERK/JNK pathway. A1R agonist induced the phosphorylation of ERK/JNK, while its antagonist could inhibit the phosphorylation [19, 28, 29] . Our results are consistent with these previously published reports, suggesting that DPCPX may inhibit tumor progression in part via the ERK/JNK pathway (Fig. 7) .
In summary, we demonstrated for the first time that A1R was the main subtype of ARs and was up-regulated in RCC cells. The A1R antagonist DPCPX inhibited the proliferation, tumor growth, and migration in RCC cells. Further investigation revealed that DPCPX promoted RCC cell apoptosis and induced an S phase cell cycle arrest through the ERK/JNK pathway. Our results suggest a potentially important role of DPCPX in the control of RCC cell proliferation and migration by regulating the ERK/JNK signaling pathway.
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